<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article article-type="research-article">
  <?properties open_access?>
  <!-- Original-type: ra-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">11720456</article-id>
      <article-id pub-id-type="pmc">2375237</article-id>
      <article-id pub-id-type="pii">6692071</article-id>
      <article-id pub-id-type="doi">10.1054/bjoc.2001.2071</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Regular Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>G-S</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>K-Y</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Perng</surname>
            <given-names>R-P</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Chest Department, Taipei Veterans General Hospital; School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC</aff>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>09</month>
        <year>2001</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2001</year>
      </pub-date>
      <volume>85</volume>
      <issue>9</issue>
      <fpage>1247</fpage>
      <lpage>1250</lpage>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>12</month>
          <year>2000</year>
        </date>
        <date date-type="rev-recd">
          <day>16</day>
          <month>05</month>
          <year>2001</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>07</month>
          <year>2001</year>
        </date>
      </history>
      <copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement>
      <copyright-year>2001</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research Campaign</copyright-holder>
      </permissions>
      <abstract>
        <p>4 patients with advanced non-small-cell lung cancer (NSCLC) treated with docetaxel developed life-threatening pneumonitis requiring mechanical ventilation. Docetaxel (30&#x2013;60&#x2008;mg m<sup>&#x2212;2</sup>, according to a different protocol) was infused within one hour with standard premedications. One patient's pneumonitis occurred 5 days after the first dose of docetaxel, and that of the other 3 between the 2nd and 6th cycles. Based on the clinical course, radiological findings of an interstitial pneumonitis, and exclusion of other possible resultant causes, including metastatic cancer, radiation pulmonary injury, infection, or connective tissue disease, hypersensitivity pneumonitis was diagnosed. The patients were treated with hydrocortisone at 1200&#x2008;mg per day or methylprednisolone at 240&#x2008;mg per day. Although 3 of the 4 had a partial improvement in lung oxygenation, all patients&#x2019; conditions of hypersensitivity pneumonitis persisted and were complicated by other events, such as hospital-acquired infection and tension pneumothorax. The presence of this unusual hypersensitivity pneumonitis, which was so severe as to be life-threatening and refractory to high-dose corticosteroid therapy, should be taken into account during docetaxel treatment. &#xA9; 2001 Cancer Research Campaign</p>
      </abstract>
      <kwd-group>
        <kwd>docetaxel</kwd>
        <kwd>non-small-cell lung cancer</kwd>
        <kwd>hypersensitivity pneumonitis</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>
</pmc-articleset>
